| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 3.4K | 6.3% |
| Total Income | 3.4K | 6.3% |
| Expenditure | 3.2K | 6.5% |
| PBT | 150.00 | 3.5% |
| Net Profit | 107.00 | 2.7% |
| OPM | 5.40% | 0.12pp |
| NPM | 3.18% | 0.29pp |
| EPS | 0.93 | 4.5% |
Henry Schein Reports Q1 2026: Net Sales $3.4 Billion, Up 6.3%
05 May 2026 · 5 May, 3:47 pm
Summary
Henry Schein, Inc. reported a 6.3% increase in net sales for the first quarter of 2026, reaching $3.4 billion. GAAP diluted EPS increased to $0.92 from $0.88 in the same quarter of the previous year, while non-GAAP diluted EPS rose to $1.32 from $1.15. The company's Adjusted EBITDA for the quarter was $289 million, up from $259 million in the first quarter of 2025. Management reaffirmed the company's financial guidance for 2026, expecting total sales growth of approximately 3% to 5%.
Key Highlights
- 1
Henry Schein reported first quarter 2026 total net sales of $3.4 billion, an increase of 6.3% compared to the first quarter of 2025.
- 2
GAAP diluted EPS for Q1 2026 was $0.92, compared to $0.88 in Q1 2025.
- 3
Non-GAAP diluted EPS for Q1 2026 was $1.32, compared to $1.15 in Q1 2025.
- 4
Adjusted EBITDA for the quarter was $289 million, compared with $259 million in the first quarter of 2025.
- 5
Global Dental Distribution merchandise sales increased by 9.0% in the first quarter of 2026.
- 6
The company reaffirmed its 2026 non-GAAP diluted EPS guidance of $5.23 to $5.37.
- 7
Henry Schein repurchased approximately 1.6 million shares of common stock for $125 million during the first quarter of 2026.
Management Comments
Fred Lowery
I am pleased with our strong first quarter results that reflect continuing momentum from the second half of last year as we grow market share and expand gross margins. Our growth outlook, combined with the progress made on value-creation initiatives and a strong start to the year, reinforces my confidence that we will deliver on our 2026 financial guidance. I am committed to the Company’s goal of achieving greater than $200 million of annual operating income improvement within the next few years, with a $125 million run-rate by the end of 2026. These initiatives, along with continued execution of our strategic plan, will contribute to us achieving high-single digit to low-double digit earnings growth in the coming years. Over the last two months as I have immersed myself in the business and spoken with customers, suppliers and employees, it is clear that Henry Schein has great assets with a differentiated platform to serve as a trusted partner to healthcare practitioners worldwide. As we look ahead, I’m excited by the significant opportunities to accelerate growth through the use of technology, improve operational execution, and become a more agile company.
Informational and educational content only. Not investment advice.